Hizentra CIDP denied as non-formulary by Humana?

Humana's specific coverage criteria for hizentra cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Hizentra for CIDP as Non-Formulary

Humana's pharmacy and medical benefit formularies are structured by tier, and Hizentra (subcutaneous immune globulin) may be placed on a non-preferred or non-formulary tier — or covered under the medical benefit rather than the pharmacy benefit — creating a coverage gap or higher cost-sharing that triggers a practical denial. A non-formulary denial does not mean the drug is medically inappropriate; it means the plan has not automatically pre-approved coverage at the preferred cost level.

For a condition like CIDP, where immune globulin therapy may be the only effective maintenance option for a given patient, non-formulary denials are routinely overturned on formulary exception request when documentation demonstrates that no formulary alternative is clinically equivalent for that individual.

## Federal Appeal Rights

• Formulary exception process: Humana is required by CMS rules (for Medicare plans) and by most state laws (for commercial plans) to have a formulary exception process. A formulary exception, supported by a prescriber attestation that no formulary alternative is appropriate, is the fastest path.
• ACA §2719 / external review: If a formulary exception is denied and the denial constitutes an adverse benefit determination, you may pursue internal appeal and then independent external review. The standard external-review deadline is approximately four months from the denial date; expedited review is available for urgent cases.
• ERISA §503: Self-funded plans must provide the specific formulary criterion applied and a full-and-fair review.

## What to Gather

1. Formulary alternative contraindication or failure documentation — chart notes or prescriber letter explaining why each Humana-preferred formulary immune globulin product is not appropriate for this patient (prior adverse reactions, route-of-administration requirements, or other clinical factors). 2. Diagnosis confirmation — neurology notes and objective testing establishing the CIDP diagnosis. 3. Prescriber medical-necessity letter for formulary exception — states that Hizentra specifically is medically necessary and that formulary alternatives are clinically inadequate for this patient. 4. Humana's formulary and exception policy — obtain the current formulary tier listing and the exception request criteria, then address each criterion explicitly. 5. Clinical course and severity — documentation of current disease activity and functional status supporting the urgency of the requested drug.

## Criteria-Mapping Structure

| Humana Formulary Exception Criterion | Supporting Evidence | |---|---| | Each stated requirement | Prescriber attestation, chart note, or date of prior failure |